Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

A Phase I, Double-masked, Placebo-controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Single Escalating Doses Of Rn6g In Patients With Dry, Age-related Macular Degeneration (Amd)

The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.

Inclusion Criteria:

• Be of non-childbearing potential.
• Diagnosis of dry AMD as defined by the Age-Related Eye Disease Study (AREDS, 2005), including uni- or multi-focal GA, without foveal involvement.
• BCVA of 20/320 or better in the worst eye.

Exclusion Criteria:

• Diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions.
• Diagnosis or history of Alzheimer's disease, dementia or neurodegenerative disorders.
• Diagnosis or recent history of clinically significant cerebrovascular disease.
• Uncontrolled hypertension.
• Uncontrolled Type 1 or Type 2 diabetes mellitus.